Puma: 3 Key Takeaways for Long-Term Investors
Puma's U.S. NERLYNX demand is heading toward a second year of growth, yet China royalties are shrinking, a split the company must balance.
Puma's recent earnings call revealed three key points for long-term investors. The company paid off the remaining loan balance to investment firm Athyrium, resulting in $108.5 million in cash and liquidity to support research and development. Management lowered full-year royalty guidance for NERLYNX, its breast cancer drug, due to increased market share of generic versions in China.
Additionally, interim results from ALISCA-Breast1 trial showed promising activity in specific biomarker groups, leading to plans for a phase III clinical study in 2027. Puma remains focused on commercializing NERLYNX, developing alisertib, and controlling expenses, with zero debt and strong liquidity as of Q3 2026.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
